NCT04767984
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 25 versions: 14 with changes below, 11 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria shortened, about 2 words
- Study completion pushed from Nov 30, 2026 to May 1, 2027
- Secondary endpoints: details revised at 2 of 4 entries
- Minor Primary completion date changed from estimate of Jan 30, 2026 to Dec 4, 2025v24
- Minor Primary completion date: Dec 31, 2025 to Jan 30, 2026
- Study completion date: Jun 30, 2026 to Nov 30, 2026
- Secondary endpoints: 6 to 4
- Study description expanded, about 2 words
Minor Trial status: Recruiting to Active, Not Recruitingv21 Show 4 more changesShow less
- Enrollment target: estimated 70 to confirmed 42
- Primary completion date: Sep 30, 2025 to Dec 31, 2025
- Study completion date: Mar 30, 2026 to Jun 30, 2026
- Site details revised at 3 of 3 sites
Notable Lead sponsor: National Cancer Institute (NCI) to Northwestern Universityv20 Show 4 more changesShow less
- Primary completion date: Dec 31, 2024 to Sep 30, 2025
- Study completion date: Dec 31, 2024 to Mar 30, 2026
- Site contacts updated at 3 of 3 sites
- Collaborators expanded, about 4 words
Show 8 earlier versionsHide 8 earlier versions
- Minor Site details revised at 1 of 3 sitesv19
- Notable Primary and study completion dates: Jun 30, 2024 to Dec 31, 2024
- Eligibility criteria shortened, about 4 words
- Study sites revised (3)
Notable Eligibility criteria expanded, about 70 wordsv16 Show 4 more changesShow less
- Study sites: 1 to 3
- Primary and study completion dates: Mar 31, 2024 to Jun 30, 2024
- Interventions: Atorvastatin Calcium (Drug), Biospecimen Collection (Procedure), Placebo Administration (Drug) to Atorvastatin Calcium (Drug), Biopsy of Colon (Procedure), Biospecimen Collection (Procedure), Placebo Administration (Drug), Questionnaire…
- Study description expanded, about 5 words
- Minor Study sites: 2 to 1v11
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Aug 31, 2023 to Mar 31, 2024
- Start date changed from estimate of Sep 27, 2021 to Sep 24, 2021
- Site details revised at 2 of 2 sites
- Notable Eligibility criteria expanded, about 64 words
- Start date: Sep 15, 2021 to Sep 27, 2021
- Notable Start date: Aug 8, 2021 to Sep 15, 2021
- Primary and study completion dates: Mar 31, 2023 to Aug 31, 2023
- Minor Study sites: 0 to 2v4
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Reduction in mutant p53 staining in biopsy samples obtained during colonoscopies done before and after intervention
Timeframe: Up to 2 years
Secondary (4)
Levels of biomarkers of Ki-67 (cell proliferation), Waf1p21 (wild type p53 allele reactivated signal), and cleaved caspase-3 (wild type p53-induced cell apoptosis)
Histological analysis for grading the severity of histologic inflammation in colorectal biopsies
Plasma concentration of cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL)
Clinical efficacy on UC related symptoms
Arms and interventions
Arm I (atorvastatin, biospecimen collection)Experimental
Patients receive atorvastatin PO QD for 12 months. Patients also undergo colonoscopy with biopsy, and collection of blood on the trial.
Arm II (placebo, biospecimen collection)Placebo comparator
Patients receive placebo PO QD for 12 months. Patients also undergo colonoscopy with biopsy, and collection of blood on the trial.
Drugs: Atorvastatin Calcium, Placebo Administration
Procedures: Biopsy of Colon, Biospecimen Collection
Other: Questionnaire Administration
Sites
3 sites in 1 country